BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9364868)

  • 1. [Acute myeloblastic leukemia showing pronounced skin infiltration during administration of low-dose cytarabine and etoposide with granulocyte colony-stimulating factor].
    Kawachi Y; Kuwajima Y; Nishihara T; Uchida T; Setsu K; Mori M; Ikeda K; Ikeda T; Sasaki K; Takahara J
    Rinsho Ketsueki; 1997 Sep; 38(9):763-9. PubMed ID: 9364868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia developed during chemotherapy for malignant lymphoma].
    Yamamoto K; Nagata K; Morita Y; Hamaguchi H
    Rinsho Ketsueki; 2002 Jun; 43(6):488-92. PubMed ID: 12134707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Continuation of complete remission by oral administration of cytarabine ocfosfate in a patient with M0, who achieved remission by small doses of cytosine arabinoside with G-CSF].
    Aoki S; Koyama S; Goto T; Takahashi H; Shibata A
    Rinsho Ketsueki; 1995 Jan; 36(1):40-4. PubMed ID: 7536275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Complete remission achieved by low-dose Ara-C, aclarubicin and rhG-CSF (CAG) therapy in acute non-lymphocytic leukemia with monosomy 7 occurring after severe aplastic anemia].
    Yamato H; Yamada K; Koike T; Yoshida M; Tsunogake S; Aoyagi M; Nakamura Y; Watanabe K; Saito K; Enokihara H
    Rinsho Ketsueki; 1995 Feb; 36(2):128-33. PubMed ID: 7536277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide].
    Yamada T; Tsurumi H; Hara T; Fukuno K; Goto H; Oyama M; Moriwaki H
    Rinsho Ketsueki; 2000 Mar; 41(3):218-21. PubMed ID: 10774251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
    Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K
    Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful treatment with idarubicin in a pediatric case of t(8;21) acute myelogenous leukemia with additional chromosomal abnormalities at relapse].
    Wakazono Y; Kataoka A; Fusaoka T; Tunamoto K
    Rinsho Ketsueki; 1998 Jul; 39(7):499-505. PubMed ID: 9750457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy.
    Kanemura N; Tsurumi H; Kasahara S; Hara T; Yamada T; Sawada M; Goto N; Kitagawa J; Shimizu M; Oyama M; Moriwaki H
    Hematol Oncol; 2008 Mar; 26(1):33-8. PubMed ID: 17918772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
    Hofmann WK; Seipelt G; Langenhan S; Reutzel R; Schott D; Schoeffski O; Illiger HJ; Hartmann F; Balleisen L; Franke A; Fiedler F; Huber C; Rasche H; Bergmann L; Ganser A; Pott C; Pasold R; Rudolph C; Ottmann OG; Gökbuget N; Hoelzer D
    Ann Hematol; 2002 Oct; 81(10):570-4. PubMed ID: 12424538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CD7(+) acute myeloid leukemia (M0) associated with a mediastinal bulky mass lesion].
    Yoshida K; Kusumoto S; Sugahara Y; Yagasaki F; Sakata T; Kawai N; Matsuda A; Suzuki T; Hirashima K; Kayano H; Bessho M
    Rinsho Ketsueki; 2001 Aug; 42(8):644-9. PubMed ID: 11579505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Auto-SCT for AML in second remission: CALGB study 9620.
    Linker CA; Owzar K; Powell B; Hurd D; Damon LE; Archer LE; Larson RA;
    Bone Marrow Transplant; 2009 Sep; 44(6):353-9. PubMed ID: 19289999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia].
    Takeyama H; Kajiguchi T; Miyata Y; Saito M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):873-8. PubMed ID: 10897214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.